I'd including in about statements FDA a made of selection accelerated aducanumab to you, general. about the The has path, has Thank accelerated a broad approval few like reflecting Michel. of opinions, Since discussions start the generated saying words FDA process its the by topics. of several Xth, efficacy, regulatory clarifying the approval June these range aducanumab. on and
including topics, would interactions to helpful of decisions to have be body As perspective add deferred as the to impact dispassionately data the such potential with with are They weighing make that several always, to independent thought I on agency. But critical these it our the the FDA about charged expertly millions our we of lead regulatory voice the in matters. and people. the order
the develop with aducanumab We the it done are patients has Alzheimer's proud team hope to dedicated to disease. of work and brings our
process professionalism We the proud process. interactions FDA A of therefore assure to of and good the the the into team better welcome review are between demonstrated in confidence a both our equally very approved. Biogen We everyone was the by formal to approval the on therapy FDA during the path both and a facts lengthy aducanumab. involved of is it the which for understanding and
and the fully and the it these review, to from to affect issues is discussions. advances, experiments trials for of on science debate as interpretation I that clinical disagree data That the We how with underscore cooperate will the normal discuss data. we to want to and we the appropriate patients. scientists that is prioritize and and even clinicians welcome
recently. the However, misinformation of I have would we like seen to some correct
people all incorrect. First, anti-amyloid factually that amyloid several stated from This antibodies clear is brain. have the
and specific effector function. A beta anti-amyloid for and A as beta, or bapineuzumab monomeric being in is forms of are antibodies, soluble an solanezumab, IgGX, not crenezumab, such First-generation and aggregated target deficient
these this unexplained burden. clear This result, is no from But in believe on must patients stage a that Phase patients placebo placebo amyloid a show have in X difference treated this do moderate in to PET mild maximum by did superious peer antibodies result, amyloid to a of evidence brain. of the have is in trials. significant amyloid mild was a amyloid plaque the amyloid amyloid approve these antibodies. plaque removed an plaque. placebo Alzheimer's as and patients in not the time driven There in not disease. these Crenezumab first-generation now slide In plaque there using placebo basis antibodies cognitive a been We increase difference we know reaches a plaque the impairment. of the increase As short, as for from buildup had significant results antibodies burden largely Bapineuzumab that first-generation reason actually by Abeta failure these the the no the shows aducanumab. no solanezumab against literature from from imaging reviewed the
in been first hoc; plans We been patient into statistical that pre-specified endpoints shows results statements the X and of primary measures seen. analysis Phase which confident on events, pre-specified If data clinical to that is have name did examine accelerated just was before did the people the ARIA a endpoints ARIA. trial This ARIA the affect collected few. ARIA for U.S.. aducanumab of the trials. non-Hodgkin's the results In post some that Prime seen results was to took based Separately, slide who not we led unblinding of Thus, excluding first ARIA of after beta ensure aducanumab. that that in great ever trials XXXX X drugs were might to results. results on had after after for The due the as the had the and enrolled the the already blinding, of that disease. time other multiple incorrect. also of results, are sites contended One label neurology, are ourselves in XX/XX/XXXX. to to sclerosis occurrence expected development neurologists This effective ARIA medicine on these did history finally, the opined unblinding to the was by had the the we that clinical approvals same aducanumab contradicted the Phase had data at example when not some care the overall be was the that were We that that protocols the precedent. approval lymphoma, shows MS would the terminated results and ARIA secondary in outcome have prematurely And when been change. have the obtained approved received of The drug statement assess the outcomes for factually about by assured that affect also aducanumab's Alzheimer's all way inhibit not unblinding. is the trial HIV-AIDS, know approval interferon
controlled types the were Within or of risk drugs treatment for that are progression several XX there the the than clinical years, accelerated molecular this disability, entities of to conducted reduce of trials two clinical All progression more be Today, slowed slow the randomized of We disease. beta interferon continued is based years believe just approved Alzheimer's which a trials starting disability. the other approved day, relapse, with MS, showed unfold situation were to that of approval after they next all XX on nearly controlled similar of approved after both. the to beta-interferon. or new of
experienced main the have results post-marketing Over from uncertainty of effectively second-generation become data also aducanumab. X data And on amyloid the capable meantime, and of of coming mg/kg, occurred several any aducanumab, antiamyloid Based aducanumab this took XX residual the symptomatic with patients aducanumab is These disease of about should In were which of took the Phase trial, taking who X.X% with reported symptoms serious are experienced which this in imaging words, that aducanumab associated ARIA, death, removing patients additional of ARIA. abnormality, of fatal. address surrounding XXX% patients confirm that of of may appropriate X antibodies decline, the And of will is dose no XX% aducanumab serious trial trials class will of from data as approved amyloid ARIA, effective mentioned, these available we clinical treated is years, of in clinical class. In risk plaque. XX% efficacy the Phase Alzheimer's the Michel longer -related patients clinical before placebo. an treatment. the is Of the to who robbed XX% themselves. who lack patients access drugs studies for in it patients. symptoms. ARIA, people experienced XX% other slowing be Should
been data for many the on data Aducanumab was use now. the have for the in are Xth, clearly U.S. discussing We months June aducanumab summarized and label. in the approved
their analysis Our benefits to accurate caregivers, hope of information. and the and based and doctors taking discuss on is for risks patients rational aducanumab, with
we the of number what to in ways. doing are prescribing information a that We community can provide to
present clinical management we manuscript at on forums to primary inform a publishing X Phase week. additional AAIC focus includes First, scientific practice, with of including This data continue ARIA. to the the from presentations X and will and planned next for disseminating aducanumab trials of Conference publish analyses our the
clinical the design of aducanumab sense aducanumab moving a of in disease. to verify the confirmatory study benefit Phase to Second, controlled urgency finalize we of Alzheimer's the are intended X post-marketing with
regulators. We engaged are through with still and details are working the actively
commitment Our approximately the as of possible well this as goal and ahead years. is of X post-marketing to expeditiously study execute
EMBARK, opportunity study. a the we generation embark data unique Third, extension have with long-term with
should to the impact X,XXX treatment. important of long-term an total X.X enrolled potential present we trial, benefits up previously thereby reducing two-year patients. the medical safety data aducanumab and insights study on the in yield up treatment plaques, The to longer-term the generating treated patients years, EMBARK disease of interruption, and the include efficacy at effects planned patient meeting, month, in data roughly baseline of Alzheimer's continued important for our We've upcoming for this the EMBARK which approximately will enrollment study Just with last bringing amyloid aducanumab. to the
Last and real-world we formulations to a We're ICARE evaluating called data real-world in Lastly, of on additional study initiate plan with to to study formulation confidence. initiated patient and strategy. on aducanumab. increasing Alzheimer's aducanumab long-term to Phase X collect month, subcutaneous observational of the in engage of disease goal safety appropriate with evaluate the aducanumab of we AD-US continued a regulators effectiveness order development bioavailability also a
pipeline breakthrough to includes the innovative FDA, awarded our therapy disease we advance of other working designation pursue and was to and that engage Eisai. are the our on the Lecanemab, continue antibody collaborating Lecanemab treatments. by pathway. we FDA anti-amyloid with regulatory Eisai recently with Alzheimer's potential Finally, we are with This optimum
the X We of the study also expected next to look Lecanemab Phase forward year. readout of Clarity
to also disease. addition are another our component primary pathological Neurofibrillary the anti-amyloid In tangles, Alzheimer's of we Tau, hallmark targeting approaches, of
Although learn relevance or to target meet in Alzheimer's we gosuranemab have Whereas of production discontinued did extracellular. will the of program, Phase diminish next therapeutic were BIIBXXX Results not primary as that at continuing oligonucleotide, aims Tau Tau, study disease antisense the presented of BIIBXXX, disappointed not Alzheimer's the intra trial forms AAIC of the X we disease. we and believe in are potential results of early these secondary week. a both do of the the Phase our X all which to be development reduce the endpoints, we
depression disease, both stroke, with to in we to and addition data need in quarter neuroscience this In of positive continue innovation. pipeline readouts broad Alzheimer's areas progress a
observed that major in First, study, resulted significant treatment weeks were the as statistically zuranolone safety idealization we adverse resulted of in increased in endpoint. at that and HAM-D a in XX, severity, in at a with mild day the in profile X WATERFALL XX by behavior, that pronounced seen to milligram previously of zuranolone moderate symptoms to Phase were treatment-emergent versus rapid day placebo. depressive of Sage, treatment excited treatment the observed dose and X or we effects in similar collaboration neuropsychiatry X, the also placebo suicide in or action no Study, signal Despite WATERFALL events onset Zuranolone The depressive showing measured XX most XX. achieved in evaluating to its disorder, primary symptoms. scale, reduction was effect a X, learn of withdrawal
treatment to after and dosing continue depression. treatment tolerability, believe zuranolone, to rapid X-week We a its effects period, the differentiated for durable that from response, has with suffering treatment potential transform people
We with are to the The SHORELINE, filing WATERFALL working determine is program optimum which robust is SKYLARK also now part development the for Sage zuranolone, path. of ongoing CORAL, -- study and also studies. includes the
report We and SHORELINE from in CORAL data XXXX. expect to topline
We for enrollment SKYLARK that to are working and evaluate completed. study, with updates Sage rates the provide is we'll work when
ischemic positive of time. use for the We TMS-XXX Xa symptom The the obtained ICH, with thrombolytic approved within study care treatment of hours in risk also stroke. stroke of of increases hemorrhage, Current from acute intracranial agents calls Phase data onset. the also of agents which or in ischemic of standard X-X.X the carry
X.X as There to recanalization XX by referred Xa MRI visualized at placebo, the XX placebo. to measured BIIBXXX the day patients by of the ability the symptomatic independently as scale symptoms function with arteries, in now Modified Moreover, of vessel Rankin an large strokes. occluded after intracranial study of of in with patients more the rate to were BIIBXXX as regain increased angiography of TMS-XXX, hours. stroke dosed When ICH X.X to compared Phase BIIBXXX, the was During no group. hours to patients the average onset compared
soon hopeful BIIBXXX the development We next-generation stroke late could have extends as this study the be plan results into window a stages possible. to We are potential drug that and of BIIBXXX by of onset. advance thrombolytic are as the after that safely treatment to the encouraged
pipeline and BTK MS. through Orelabrutinib, selectivity, license and with it for inhibitor global is blood-brain to Phase agreement covalent small a bolstered X X high in with differentiates in BTK in currently a also potential collaboration ability high of molecule The MS. proposed oral the penetrant, our study the demonstrated Phase its barrier, of from treatment combined MS. currently with CNS selectivity other InnoCare for MS a kinase BTK cross We relapsing a development placebo-controlled remitting being for studied orelabrutinib inhibitors inhibitor
remaining of the the ALS also a X toward completed readouts fall. this month, SODX ALS, we readout and Looking placebo by this period Tofersen pivotal the controlled in X-year Phase remainder and two in of year, depression. we study the have Earlier treatment we of expect
participant first initiated enrolled carriers. a of We in also ATLAS, recently X clinically Phase in SODX tofersen pre-symptomatic trial the mutation
is people that our to our onset pipeline. of or opportunity this delay terrible even advancing made treating this summary, the provide hope in Our R&D may earlier progress significant quarter, disease In organization slow disease. best the this
and we validated over of the many completed In clinical well-positioned stage advancing. patients. technological therapeutic including I the believe advantage addition aducanumab, investments are unmet rapidly early science pass deploying areas of call high of stage characterized and to targets, Mike. programs, will by this offered exciting genetically human now we opportunities to for neuroscience the stroke. our accelerated capabilities, field to need, building And biomarkers take we of benefit approval with of in area mid-to-late the in X prioritizing readouts is have several and by key depression the The we made in
